

UNIVERSITAT DE BARCELONA
FACULTAT DE MEDICINA

**Estudi experimental del paper del factor activador de les
plaquetes en la meningitis i la pneumònia pneumocòciques**

Memòria presentada per M^a Carmen Cabellos Mínguez per a
optar al grau de Doctora en Medicina i Cirurgia



7. CONCLUSIONS

7. CONCLUSIONS

Respecte a la capacitat inflamatòria del factor activador de les plaquetes.

1. El factor activador de les plaquetes és inflamatori al sistema nerviós central, produint augment de la permeabilitat de la barrera hematoencefàlica amb augment de la concentració de proteïnes al LCR, i edema cerebral, però produeix només moderada pleocitosi al LCR.

2. El factor activador de les plaquetes és inflamatori al pulmó, produint augment en la concentració de proteïnes i acúmulo de leucòcits.

Respecte al paper del factor activador de les plaquetes en el curs de la meningitis i de la pneumònia pneumocòcica.

3. L'activitat inflamatòria del factor activador de les plaquetes té significat biològic a la meningitis i la pneumònia pneumocòciques, donat que el seu antagonista és capaç de reduir l'exudació de proteïnes generada per *S. pneumoniae* a l'espai subaracnoïdal i al rentat broncoalveolar.

4. L'antagonista del factor activador de les plaquetes només és capaç de reduir la presència de leucòcits generada per *S. pneumoniae* a l'espai subaracnoïdal, però no al pulmó. Això indica que el mecanisme de reclutament de leucòcits és probablement diferent al sistema nerviós central i al pulmó.

5. La combinació d'anticòs monoclonal IB4 i l'antagonista del factor activador de les plaquetes evita en gran part la presència de leucòcits generada per *S. pneumoniae* al rentat broncoalveolar. Aquest fet suggereix que pot haver-hi reclutament de leucòcits depenent del factor activador de les plaquetes i independent de la molècula CR3 dels leucòcits al pulmó, però no al sistema nerviós central.

6. L'antagonista del factor activador de les plaquetes evita la pleocitosi generada per *S. pneumoniae*, però no la generada per *H. influenzae*.

Respecte a la capacitat dels components pneumocòcics per actuar com anàlegs del factor activador de les plaquetes.

7. Existeix reactivitat creuada entre la paret cel.lular pneumocòcica i el factor activador de les plaquetes.

8. L'anticòs anti-paret TEPC-15 evita l'edema cerebral produït pel factor activador de les plaquetes, però no l'augment en la concentració de proteïnes.

9. L'antagonista del factor activador de les plaquetes, redueix la pleocitosi i la concentració de proteïnes, però no l'edema cerebral generats en resposta a la paret cel.lular pneumocòcica a l'espai subaracnoïdal.

10. L'antagonista del factor activador de les plaquetes és incapaç de reduir la inflamació produïda per l'àcid lipoteicoic pneumocòcic a l'espai subaracnoïdal.

11. La paret cel.lular pneumocòcica i l'àcid lipoteicoic pneumocòcic no tenen activitat similar al factor activador de les plaquetes, ni capacitat d'inhibició competitiva en assaigs específics pel factor activador de les plaquetes d'agregació plaquetar i de degranulació de neutròfils.

12. La intensitat de la inflamació associada amb la infecció pneumocòcica al sistema nerviós central i al pulmó està augmentada per una especial participació del factor activador de les plaquetes endogen en la resposta inflamatòria als components de la paret cel.lular pneumocòcica.

8. BIBLIOGRAFIA

8. BIBLIOGRAFIA

1- Durack DT. Pneumococcal pneumonia. In Wyngaarden JB and Smith LH. Cecil Textbook of Medicine, 18th ed. Philadelphia: W.B.Saunders Company, 1988: 1554-1561.

2- Liñares J, Pérez JL, Garau J, Murgui L, Martin R. Comparative susceptibilities of penicillin-resistant pneumococci to cotrimoxazole, vancomycin, rifampicin and fourteen β -lactam antibiotics.

J. Antimicrob. Chemother. 1984; 13:353-359.

3- Viladrich PF, Gudiol F, Liñares J, Rufí G, Ariza J, Pallarés R. Characteristics and antibiotic therapy of adult meningitis due to penicillin-resistant pneumococci.

Am J: Med. 1988; 84: 839-845.

4- Klebs E. Beiträge zur kenntnis der schistomyceten. 4 die monadien.

Arch. Exper. Path. Paharmakol. 1875;4:409-488.

5- Avery OT, McLeod CM, McCarthy M. Studies on the chemical nature of the substance inducing transformation of pneumococcal types. Induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III.

J. Exp. Med. 1944; 79:137-158.

6- Roberts RB. *Streptococcus pneumoniae*. In Mandell GL, Gordon DR Jr, Bennett JE. Principles and practices of Infectious Diseases, 2nd ed. Willey Medical Publications.

7- Sternberg GM. The etiology of croupous pneumonia. *Natl. Med. Rev.* 1897; 7:175-177.

8- Sweath PH, Mair NS, Sharpe ME, Holt JG. ed. Bergey's manual of systematic bacteriology. Williams and Wilkins editorial. Baltimore 1986.

9- García E, García JL, Ronda C, García P, López R. Cloning and expression of the pneumococcal autolysin gene in *E. coli*. *Mol. Gen. Genet.* 1985; 201:225-230.

10- Pozzi G, Oggioni MR, Tomasz A. DNA probe for identification of *Streptococcus pneumoniae*. *J. Clinical Microbiology.* 1989; 27:370-372.

11- Formanek H, Formanek S, Wawra H. A three dimensional atomic model of the murein layer of bacteria. *Eur. J. Biochem.* 1974; 46: 279-294.

12- Tomasz A. Choline in the cell wall of a bacterium: novel type of polymer-linked choline in pneumococcus. *Science.* 1967; 157:694-697.

13- Holtje JV, Tomasz A. Specific recognition of choline residues in the cell wall teichoic acid by the N-acetylmuramyl-L-alanine amidase of pneumococcus.

J. Biol. Chem. 1975; 250:6072-6076.

14- Tomasz A. Surface components of *Streptococcus pneumoniae*.

Rev. Infect. Dis. 1981; 3:190-211.

15- Briles DE, Forman C, Hudak S, Chaffin JL. Antiphosphorylcholine antibodies of the T-15 idiotyp are optimally protective against *Streptococcus pneumoniae*.

J. Exp. Med. 1982; 156:1177-1785.

16- Yother J, Forman C, Gray BM, Briles DE. Protection of mice from *Streptococcus pneumoniae* by anti-phosphocholine antibody.

Infect. Immun. 1982; 36: 184-188.

17- Wallick S, Claffin JL, Briles DE. Resistance to *Streptococcus pneumoniae* induced by a phosphocholine-protein conjugate.

J. Immunol. 1983; 130: 2871-2875.

18- Szu SC, Clarke S, Robbins JB. Protection against pneumococcal infection in mice conferred by phosphocholine-binding antibodies: specificity of the phosphocholine

binding and relation to several types.

Infect. Immun. 1983; 39: 993-999.

19- Musher DM, Watson DA, Baughn RE. Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection?

J. Infect. Dis. 1990; 161:736-740.

20- Winkelstein JA, Tomasz A. Activation of the alternative complement pathway by pneumococcal cell wall teichoic acid.

J. Immunol. 1978; 120:174-178.

21- Tomasz A. Saukkonen K. The nature of cell wall-derived inflammatory components of pneumococci.

Pediatr. Infect. Dis. J. 1989; 8: 902-903.

22- Tuomanen E, Tomasz A, Hengstler B, Zak O. The relative role of bacterial cell wall and capsule in the induction of inflammation in pneumococcal meningitis.

J. Infect. Dis. 1985; 151:535-540.

23- Tuomanen E, Liu H, Hengstler B, Zak O, and Tomasz A. The induction of meningeal inflammation by components of the pneumococcal cell wall.

J. Infect. Dis. 1985; 151:859-868.

24- Tuomanen E, Rich R, Zak O. Induction of pulmonary inflammation by components of the pneumococcal cell surface.

Am Rev. Resp. Dis. 1987; 135:869-874.

25- Reisenfeld-Orn I, Wolpe S, García-Bustos JF, Hoffman MK, Tuomanen E. The production of interleukin-1 but not tumor necrosis factor by human monocytes stimulated with pneumococcal cell surface components.

Infect. Immun. 1989; 57:1890.

26- Lacks S, Neuberger M. Membrane location of a deoxyribonuclease implicated in the genetic transformation of *Diplococcus pneumoniae*.

J. Bacteriol. 1975; 124:1321-1329.

27- Horne D, Plotch S, Tomasz A. Cell surface components implicated as attachment sites for the pneumococcal competence activator. In Portoles A. Bacterial transformation and transfection: Proceedings of the third European Meeting on Genetic transformation. North Holland, Amsterdam, 1977:11-34.

28- Williamson R, Hakenbecky R, Tomasz A. The penicillin binding proteins of *Streptococcus pneumoniae* grown under lysis permissive and lysis-protective (tolerant) conditions.

F.E.M.S. Microb Letters 1980; 7: 127-131.

29- Goebel WF, Shedlovsky T, Lavin GI, Adams MH. The heterophile antigen of pneumococcus.

J. Biol. Chem. 1943; 148: 1-15.

30- Briles EB, Tomasz A. Pneumococcal Forssman antigen, a choline-containing lipoteichoic acid.

J. Biol. Chem. 1973; 248: 6394-6397.

31- Fujiwara M. The Forssman antigen of pneumococcus. **Japn. J. Exp. Med. 1967; 37: 581-592.**

32- Holtje J, Tomasz A. Biological effects of lipoteichoic acids.

J. Bacteriology 1975; 124:1023-1027.

33- Ripley-Petzoldt ML, Giebink GS, Juhn SK, Aeppli D, Tomasz A, Tuomanen E. The contribution of pneumococcal cell wall to the pathogenesis of experimental otitis media.

J. Infect. Dis 1988; 157:245-255.

34- Bruyn GAW, Van der Meer JWM, Hermans J, Knoppert W. Pneumococcal bacteremia in adults over a 10-year period at University hospital, Leiden.

Rev. Infect. Dis. 1988; 10:446-450.

35- Ruben FL, Norden CW, Korica Y. Pneumococcal bacteremia at a medical/surgical hospital for adults between 1975 and 1980.

Am. J. Med. 1984; 77:1091-1094.

36- Alexander JD Jr, Flippin HF, Eisenberg GM. Pneumococcal meningitis . Study of one hundred two cases.

Arch. Intern. Med. 1953; 92:440-447.

37- Fernandez-Viladrich P, Buenaventura I, Gudiol F, et al. Meningitis neumocócica del adulto. Estudio de 141 episodios.

Med. Clin. (Barc) 1986; 87:569-574.

38- Saballs P, Barrufet P, Force LL, García A, Verdaguer A, Drobnic L. Meningitis bacterianas recidivantes: A proposito de 21 pacientes con 64 brotes.

Med. Clin (Barc) 1983; 81: 385-388.

39- Tugwell P, Greenwood BM, Warrell DA. Pneumococcal meningitis: A clinical and laboratory study.

Quarterly J. Med. 1976; 65:583-601.

40- Scheld WM, Park PS, Dacey RG, Winn HR, Jane JA, Sande MA. Clearance of bacteria from cerebrospinal fluid to blood in experimental meningitis.

Infect. Immun. 1979; 24:102-105.

41- Tunkel AR, Wispelwey B, Scheld WM. Bacterial meningitis: Recent advances in pathophysiology and treatment.

Ann. Intern Med. 1990; 112:610-623.

42- Simberkoff MS, Moldover NH, Rahal JJ. Absence of detectable bactericidal and opsonic activities in normal and infected cerebrospinal fluids.

J. Lab. Clin. Med. 1980; 95:362-372.

43- Gigliotti F, Lee D, Insel RA, Scheld WM. IgG penetration into the cerebrospinal fluid in a rabbit model of meningitis.

J. Infect Dis. 1987; 156:394-398.

44- Sande MA, Scheld WM, McCracken GH Jr, and the Meningitis Study Group. Report of a workshop: Pathophysiology of bacterial meningitis-Implications for new management strategies.

Pediatr. Infect. Dis. J. 1987; 6:1145-1170.

45- Sande MA, Täuber MG, Scheld WM, McCracken GH Jr, and the Meningitis Study Group. Report of a second workshop: Pathophysiology of bacterial meningitis.

Pediatr. Infect. Dis. J. 1989; 8: 901-932.

46- Zwahlen A, Nydegger VE, Vadaux P, Lambert PH,

Waldvogel FA. Complement mediated opsonic activity in normal and infected human cerebrospinal fluid early response during bacterial meningitis.

J. Infect Dis. 1982; 145:635-646.

47- Greenwood BM. Chemotactic activity of cerebrospinal fluid in pyogenic meningitis.

J. Clin Pathol. 1978; 31:213-216.

48- Wyler Dj, WAserman SI, Karchmer AW. Substances wich modulate leukocyte migration are present in CSF during meningitis.

Ann. Neurol. 1979; 5:322-326.

49- Tuomanen E, Saukkonen K, Sande S, Cioffe C, Wright D. Reduction of inflammation, tissue damage and mortality in bacterial meningitis in rabbits treated with monoclonal antibodies against adhesion-promoting receptors of leukocytes.

J. Exp. Med. 1989; 170:959-969.

50- Täuber MG, Borschberg U, Sande MA. Influence of granulocytes on brain edema intracranial pressure, and cerebrospinal fluid concentrations of lactate and protein in experimental meningitis.

J. Infect. Dis. 1988; 157:456-464.

51- Ernst JD, Decazes JM, Sande MA. Experimental pneumococcal meningitis: Role of leukocytes in pathogenesis.

Infection and Immunity. 1983; 41:275-279.

52- Tuomanen E. Partner drugs: A new outlook for bacterial meningitis.

Ann Intern Med. 1988; 109: 690-692.

53- Tuomanen E, Hengstler B, Rich R, Bray MA, Zak O, Tomasz A. Nonsteroidal anti-inflammatory agents in the therapy for experimental pneumococcal meningitis.

J. Infect. Dis. 1987; 155:985-990.

54- Kadurugamuwa JL, Hengstler B, Zak O. Cerebrospinal fluid protein profile in experimental pneumococcal meningitis and its alteration by ampicillin and anti-inflammatory agents.

J. Infect. Dis. 1989; 159:26-34.

55- Mustafa MM, Ramilo O, Mertsola J, Risser RS, Beutler B, Hansen EJ, Mc Cracken GH Jr. Modulation of inflammation and cachectin activity in relation to treatment of experimental *Haemophilus influenzae* type B meningitis.

J. Infect. Dis. 1989; 160:818-825.

56- Ernst JD, Hartiala KT, Goldstein IM, Sande MA. Complement (C5)-derived chemotactic activity accounts for accumulation of polymorphonuclear leukocytes in cerebrospinal fluid of rabbits with pneumococcal meningitis.

Infect. Immun. 1984; 46:81-86.

57- Mustafa M, Ramilo O, Saenz-Llorens X, Mertsola J, McCracken GH Jr. Role of tumor necrosis factor in experimental and clinical bacterial meningitis.

Pediatr. Infect. Dis. J. 1989; 8:907-908.

58- Quagliarello UJ, Long WJ, Scheld WM. Human interleukin-1 modulates blood-brain barrier injury *in vivo*. Program and Abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy. New York, 1987 (Abstract 614).

59- Ramilo O, Mustafa M, Saenz-Llorens X et al. Role of Interleukin-1 β in meningeal inflammation.

Pediatr. Infect. Dis. J. 1989; 8: 909-910.

60- Tuomanen E, Hengstler B, Zak O, Tomasz A. The role of complement in inflammation during experimental pneumococcal meningitis.

Microb Pathogen 1986; 1: 15-32.

61- Ramilo O, Saez-Llorens X, Mertsola J, Jafari H, Olsen KD, Hansen EJ, Yoshinaga M, Ohkawara S, Nariuchi H, McCracken GH Jr. Tumor necrosis factor α /cachectin and interleukin 1 β initiate meningeal inflammation.
J. Exp. Med. 1990; 172: 497-507.

62- Scheld WM, Quagliarello VJ, Lesse AJ. Selected aspects of the pathogenesis and pathophysiology of bacterial meningitis.
In: Williamson JA, Burnie J. Bacterial meningitis. Londres: Academic Press, 1987: 1-28.

63- Niemöller VM, Täuber MG. Brain edema and increased intracranial pressure in the pathophysiology of bacterial meningitis.
Eur. J. Clin. Microbiol. Infect Dis. 1989; 8: 109-117.

64- Scheld WM. Drug delivery to the central nervous system: general principles and relevance to therapy for infections of the CNS.
Rev. Infect. Dis. 1989; 11 (Supl 7): S1669-S1690.

65- Täuber MG, Khayam-Bashi H, Sande MA. Effects of ampicillin and corticosteroids on brain water content, cerebrospinal fluid pressure and cerebrospinal fluid pressure and cerebrospinal fluid lactate levels in experimental pneumococcal meningitis.

J. Infect. Dis. 1985; 151:528-534.

66- Tureen JH, Stella FB, Clyman RI, Mauray F, Sande MA. Effect of indomethacin on brain water content, cerebrospinal white blood cell response and prostaglandin E₂ levels in cerebrospinal fluid in experimental pneumococcal meningitis in rabbits.

Pediatr. Infect. Dis. J. 1987; 6:1151-1153.

67- Syrogianopoulos GA, Olsen KD, Reisch JS, McCracken GH Jr. Dexamethasone in the treatment of experimental haemophilus influenzae type B meningitis.

J. Infect. Dis. 1987; 155: 213-219.

68- Taüber MG, Sande MA. Dexamethasone in bacterial meningitis: Increasing evidence for a beneficial effect.

Pediatr. Infect. Dis. J. 1989; 8:842-844.

69- Scheld WM, Dacey RG, Winn HR, Welsch JE, Jane JA, Sande MA. Cerebrospinal fluid outflow resistance in rabbits with experimental meningitis.

J. Clin. Invest. 1980; 66:243-253.

70- Tureen J. Cerebral blood flow and metabolism in experimental meningitis.

Pediatr. Infect. Dis. J. 1989; 8:917-918.

71- Ansfield MJ, Woods DE, Johanson WG. Lung bacterial clearance in murine pneumococcal pneumonia.
Infect. Immun 1977; 17: 195-204.

72- Coonrod JD, Jenkins S. Interacion of pneumococcal antigens with complement in rats.
Infect Immun. 1979; 23: 626-632.

73- Winkelstein JA, Bochini JA Jr, Schiffman G. The role of the capsular polysacharide in the activation of the alternative pathway by the pneumococcus.
J. Immunol. 1976: 116:367-370.

74- Hummell DS, Berwionger RW, Tomasz A, Winkelstein JA. The fixation of C3b to pneumococcal cell wall polymers as a result of activation of the alternative complement pathways.
J. Immunol. 1981; 127:1287-1289.

75- Coonrod JD, Yoneda K. Complement and opsonins in alveolar secretions and serum of rats with pneumonia due to *Streptococcus pneumoniae*.
Rev. Infect. Dis. 1981; 3:310-322.

76- Heidbrink PJ, Toews GB, Gross GN, Pierce AF. Mechanisms of complement mediated clearance of bacteria from the murine lung.

Am. Rev. Respir. Dis. 1982, 125: 517-520.

77- Gross GN, Rehm SR, Pierce AK. The effect of complement depletion on lung clearance of bacteria.

J. Clin. Invest. 1978; 62:373-378.

78- Toews GB, Vial WC. The role of C5 in polymorphonuclear leukocyte recruitment in response to *Streptococcus pneumoniae*.

Am. Rev. Resp. Dis. 1984; 129: 82-86.

79- Vial WC, Toews GB, Pierce AK. Early pulmonary granulocyte recruitment in response to *Streptococcus pneumoniae*.

Am. Rev. Respir. Dis. 1984; 129: 87-91.

80- Braquet P, Touqui L, Shen TY, Vargaftig BB. Perspectives in platelet activating factor research.

Pharmacological Reviews. 1987; 39:97-145.

81- Braquet P, Vargaftig BB. Pharmacology of platelet activating factor.

Transplantation Proceedings. 1986; 5(S4): 10-19.

82- Henson PM. Release of vasoactive amines from platelets induced by sensitized mononuclear leukocytes and antigen.

J. Exp. Med. 1970; 131:287-304.

83- Siraganian RP, Osler AG. Destruction of rabbit platelets in the allergic response of sensitized leukocytes. I. Demonstration of a fluid phase intermediate.

J. Immunology 1971; 106:1244-1251.

84- Benveniste J, Henson PM, Cochrane CG. Leukocyte dependent histamine release from rabbit platelets. The role of IgE, basophils and a platelet activating factor.

J. Exp. Med. 1972; 136:1356-1377.

85- Pinckard RN, Farr RS, Hanahan DJ. Physiochemical and functional identity of rabbit platelet-activating factor (PAF) released *in vivo* during IgE anaphylaxis with PAF released *in vitro* from IgE sensitized basophils.

J. Immunol. 1979; 123:1847-1857.

86- Benveniste J, Tence M, Varenne P, Bidault J, Boullet C, Polonsky J. Semisynthese et structure proposée du facteur activant les plaquettes (PAF): PAF acether, un alkyl ether analogue de la lysophosphatidylcholine.

C. R. Acad. Sci. (Paris). 1979; 289:1037-1040.

87- Blank ML, Snyder F, Byers LW, Brooks B, Muirhead EE. Antihypertensive activity of an alkyl ether analog of

phosphatidylcholine.

Biochem Biophys Res. Commun 1979; 90:1194-1200.

88- Demopoulos CA, Pinckard RN, Hanahan DJ. Platelet activating factor: Evidence for 1-O-alkyl-2-acetyl-sn-glycerol-3-phosphorylcholine as the active component: A new class of lipid chemical mediators.

J. Biol. Chem. 1979; 254:9355-9358.

89- Benveniste J, Arnoux B. Platelet activating factor and structurally related ether-lipids.

Proceedings of the 1st international symposium on platelet activating factor and structurally related ether-lipids. Elsevier Science Publishers. 1983.

90- Oda M, Satouchi K, Yasunaga K, Saito K. Molecular species of platelet activating factor generated by human neutrophils challenged with ionophore A23187.

J. Immunol. 1985; 134:1090-1093.

91- Snyder F. Platelet activating factor and related acetylated lipids as potent biologically active cellular mediators.

Am. J. Physiol. 1990; 259:697-708.

92- McIntyre TM, Zimmerman GA, Satoh K, Prescott SM. Cultured endothelial cells synthesize both platelet-

activating factor and prostacyclin in response to histamine, bradikinin, and adenosine triphosphate.

J. Clin. Invest. 1985; 76:271-280.

93- Lewis MS, Whatley RE, Cain P, McIntyre TM, Prescott SM, Zimmerman GA. Hydrogen peroxide stimulates the synthesis of platelets activating factor by endothelium and induces endothelial cell-dependent neutrophil adhesion.

J. Clin. Invest. 1988; 82:2045-2055.

94- Lefer AM. Platelet activating factor (PAF) and its role in cardiac injury.

Prog. Clin. Biol. Res. 1989; 301:53-60.

95- Henson PM. PAF-A perspective.

Am. J. Respir. Cell Mol. Biol. 1989;1:263-265.

96- Wardlow ML, Cox CP, Mewg KE, Greene DE, Farr RS. Substrate specificity and partial characterization of the PAF-acylhidrolase in human serum that rapidly inactivates platelet-activating factor.

J. Immunology 1986; 136:3441-3446.

97- Camussi G, Aglietta M, Coda R, Bussolino F, Piacibello W, Tetta C. Release of platelet activating factor and histamine II the cellular origin of human PAF: Monocytes, polymorphonuclear neutrophils and basophils.

Immunology 1981; 42:191-199.

98- Sánchez-Crespo M, Iñarrea P, Gómez-Cambronero J. Platelet activating factor, a secretory product from phagocytes. *In* Platelet activating factor and related lipid mediators. Fred Snyder ed. Plenum Publishers Corporation 1987.

99- Sisson JH, Prescott JM, McIntyre TM, Zimmerman GA. Production of platelet activating factor by stimulated human polymorphonuclear leukocytes.
J. Immunology 1987; 138: 3918-3926.

100- Elstad MR, Prescott SM, McIntyre TM, Zimmerman GA. Synthesis and release of platelet-activating factor by stimulated human mononuclear phagocytes.
J. Immunology 1988; 140: 1618-1624.

101- Baggiolini M, Dewald B, Thelen M. Effects of PAF on neutrophils and mononuclear phagocytes.
Prog. Biochem Pharmacol. 1988; 22:90-105.

102- Pignol B, Henane S, Mencia-Huerta JM. Effect of platelet activating factor and its specific receptor antagonist, BN 52021 (Ginkgolide B) on interleukin 1 release and synthesis by rat spleen adherent monocytes.*In*

Ginkgolides-chemistry, biology, pharmacology and clinical perspectives. P. Braquet ed. J.R. Prous Science Publishers 1988.

103- Rola-Pleszczynski M. Lymphocyte function as modulated by platelet activating factor (PAF-acether) and its receptor antagonist BN 52021. In Ginkgolides-chemistry, biology, pharmacology and clinical perspectives. P. Braquet ed. J.R. Prous Science Publishers 1988.

104- Rola-Pleszczynski M. PAF in cellular Immunology. Prog. Biochem. Pharmacol. 1988; 22:81-89.

105- Gomez J, Bloom JW, Yamamura HI, Halonen M. Characterization of receptors for platelet activating factor in guinea pig lung membranes. Am. J. Respir. Cell Mol. Biol. 1990; 3:259-264.

106- Honda Z, Nakamura M, Miki I, Hinami M, Watanabe T, Seyama Y, Okado H, Toh H, Ito K, Miyamoto T, Shimizu T. Cloning by functional expression of platelet activating factor receptor from guinea-pig lung. Nature. 1991; 349:342-346.

107- Braquet P, Hosford D, Braquet M, Bourgain R, Bussolino F. Role of cytokines and platelet activating

factor in microvascular immune injury.

Int. Arch. Allergy Appl. Immunol. 1988; 1:984-996.

108- Ferguson-Chanowitz KM, Katocs AS, Pickett WC, Kaplan JB, Sass PM, Oronsky AL, Kerwar S. Platelet activating factor or a platelet activating factor antagonist decreases tumor necrosis factor α in the plasma of mice treated with endotoxin.

J. Infect. Dis. 1990; 162:1081-1086.

109- Lad PM, Olson CHV, Grewal IS. Platelet activating factor mediated effects on human neutrophil function are inhibited by pertussis toxin.

Biochem. Biophys. Research. Commun. 1985; 129:632-638.

110- Peplow PV, Mikhailidis DP. Platelet activating factor and its relation to prostaglandins, leukotrienes and others aspects of arachidonate metabolism.

Prostaglandins leukotrienes and essential fatty acids 1990; 41:71-82.

111- Stimler NP, Bloor CM, Hugli TE, Wycke RL, McCall CE, O'Flaherty JT. Anaphylactic actions of platelet activating factor.

Am J. Pathol. 1981; 105:64-69.

112- Harper MJ. Platelet activating factor: A

paracrine factor in preimplantation stages of reproduction?
Biol. Reprod. 1989; 40: 907-913.

113- Roudebusch WE, Minhas BS, Ricker DD, Palmer TV, Dodson MG. Platelet activating factor enhances in vitro fertilization of rabbit oocytes.
Am. J. Obstet. Gynecol. 1990; 163:1670-1673.

114- Valone FH, Coles P, Reinhold VR, Goetzl EJ. Specific binding of phospholipid platelet activating factor by human platelets.
J. Immunology 1982; 129:1637-1641.

115- Kloprogge E, De Haas GM, Gorter G, Akkerman JWN. Properties of PAF-acether induced platelet aggregation and secretion. Studies in gel filtered human platelets.
Thrombosis Research 1983; 29:595-609.

116- Kloprogge E, Akkerman JWN. Binding and kinetics of PAF-acether (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) to intact human platelets.
Biochem. J. 1984; 223: 901-909.

117- Braquet P, Bourgain R, Mencia-Huerta JM. Effect of Platelet activating factor on platelets and vascular endothelium.
Semin. Thromb. Hemost. 1989; 15:184-196.

118- Handley DA. Quantitation of *in vitro* and *in vivo* biological effects of platelet activating factor. In: Chang JY, Lewis AJ. Pharmacological methods in the control of inflammation. Alan R. Liss Inc. 1989: 23-58.

119- Hwang SB, Li ChL, Lam MH, Shen TY. Characterization of cutaneous vascular permeability induced by platelet activating factor in guinea pigs and rats and its inhibition by a platelet activating factor receptor antagonist.

Laboratory Investigation 1985; 52:617-630.

120- Doebber TW, Wu MS, Biftu T. Platelet activating factor mediation of rat anaphylactic responses to soluble immune complexes. Studies with PAF receptor antagonist L-652,731.

J. Immunology 1986; 136:4659-4668.

121- Doebber TW, Wu MS, Robbins JC, Choy BM, Chang MN, Shen TY. Platelet activating factor (PAF) involvement in endotoxin-induced hypotension in rats. Studies with PAF-receptor antagonist kadsurenone.

Biochem. Biophys. Res. Commun. 1985; 127:799-808.

122- Tereshita Z, Imura Y, Nishikawa K, Sumida S. Is platelet activating factor (PAF) a mediator of endotoxin shock?

Eur. J. Pharmacol. 1985; 109:257-261.

123- Chang SW, Feddersen ChO, Henson PM, Voelkel NF. Platelet activating factor mediators hemodynamic changes and lung injury in endotoxin-treated rats.

J. Clin. Invest. 1987; 79:1498-1509.

124- Sanchez-Crespo M, Fernandez-Gallardo S, Nieto ML, Baranes J, Braquet P. Inhibition of the vascular actions of IgG aggregates by BN52021, a highly specific antagonist of PAF-acether.

Immunopharmacology. 1985; 10:69-75.

125- López-Díez F, Nieto ML, Fernández-Gallardo S, Gijón MA, Sánchez-Crespo M. Occupancy of platelet receptors for platelet activating factor in patients with septicemia.

J. Clin. Invest. 1989; 83:1733-1740.

126- Hosford D, Paubert-Braquet M, Braquet P. Platelet activating factor and cytokine interactions in shock.

Resuscitation. 1989;18:207-218.

127- Lefer Am. Induction of tissue injury and altered cardiovascular performance by platelet activating factor: Relevance to multiple systems organ failure.

Crit. Care Clin. 1989; 5:331-352.

128- Camussi G, Pawlowski I, Bussolino F, Caldwell PRB, Brentjens J, Andres G. Release of platelet activating factor in rabbits with antibody-mediated injury of the lung: the role of leukocytes and of pulmonary endothelial cells.

J. Immunol. 1983; 131:1802-1806.

129- Pretolani M, Lellouch-Tubiana A, Lefort J, Bachelet M, Vargaftig BB. PAF-acether and experimental anaphylaxis as a model for asthma.

Int. Arch. Allergy Appl. Immunol. 1989; 88:149-153.

130- McManus LM, Deavers SI. Platelet activating factor in pulmonary pathobiology.

Clin. Chest. Med. 1989; 10:107-118.

131- Pauwels R. The pharmacology of airway hyperresponsiveness and inflammation.

Lung. 1990; 168 Suppl P: 221-229.

132- Lewis JC, O'Flaherty JT, McCall ChE, Wyckle RL, Bond MG. Platelet activating factor effects on pulmonary ultrastructure in rabbits.

Exp. and Mol. Pathol. 1983; 38:100-108.

133- Okuda Y, Hattori H, Takashima T, Miyatake A, Yamatodani A, Tsuyuguchi J, Kischimoto S. Basophil

histamine release by platelet-activating factor in aspirin-sensitive subjects with asthma.

J. Allergy Clin. Immunol. 1990; 86: 548-553.

134- González-Crussi F, Hseuh W. Experimental model of ischemic bowel necrosis. The role of platelet activating factor and endotoxin.

Am. J. Pathol. 1983; 112: 127-135.

135- Caplan MS, Hsueh W. Necrotizing enterocolitis: Role of platelet activating factor, endotoxin, and tumor necrosis factor.

J. Pediatr. 1990; 117:47-51.

136- Wallace JL, Braquet P, Ibbotson GC, McNaughton WK, Cirino G. Assessment of the role of platelet activating factor in an animal model of inflammatory bowel disease.

J. Lipid Mediators. 1989; 13-23.

137- Zhang F. Protective effect of a platelet activating factor antagonist in experimental liver injury.

Chung Hua I Hshueh Tsa Chih. 1990; 70: 375-378.

138- Fernández-Gallardo S, Gijón MA, García MC, Cano E, Sánchez-Crespo M. Biosynthesis of platelet activating factor in glandular gastric mucosa.

Biochem. J. 1988; 254:707-714.

139- Esplugues JV, Whittle BJ. Gastric effects of PAF. **Methods Find. Exp. Clin. Pharmacol.** 1989;11 Suppl 1: 61-66.

140- Wallace JL. Lipid mediators of inflammation in gastric ulcer. **Am. J. Physiol.** 1990; 258:1-11.

141- Levi R, Burke JA, Guo ZG, Hattori Y, Hoppens CM et al. Acetyl Glyceryl ether phosphorylcholine (AGEPC), a putative mediator of cardiac anaphylaxis in the guinea pig. **Circulation Res.** 1984; 54:117-124.

142- Levi R, Mullane KM. Isolated coronary-perfused mammalian heart: assessment of eicosanoid and platelet-activating factor release and effects. **Methods Enzymol.** 1990; 187:610-621.

143- Camussi G, Saldivio G. Platelet activating factor in graft rejection. **Prog. Biochem. Pharmacol.** 1988; 106-117.

144- Foegh ML, Ramwell PW. PAF and BN52021 in organ transplant rejection. In *Ginkgolides-chemistry, biology, pharmacology and clinical perspectives*. P. Braquet ed. J.R. Prous Science Publishers 1988.

145- Farkas G, Mandi Y, Koltai M, Braquet P. Graft protective effect of BN52021, a specific PAF-acether antagonist in an in vitro Langerhans islet-splenic lymphocyte model. In Ginkgolides-chemistry, biology, pharmacology and clinical perspectives. P. Braquet ed. J.R. Prous Science Publishers 1988.

146- Camussi G. Platelet activating factor and allograft rejection.

Transplantation Proceedings 1986; 5(48): 91-93.

147- Pignol B, Henane S, Pirotzky E, Mencia-Huerta JM, Braquet P. Potentiation of immunosuppressive action of cyclosporine A by platelet activating factor antagonist: an approach of the mechanism of action of these drugs in the prevention of graft rejection.

Transplantation Proceedings. 1988: 2(28): 259-265.

148- Foegh ML, Khirabadi BS, Rowles JR, Braquet P, Ramwell PW. Prolongation of cardiac allograft survival with BN 52021, a specific antagonist of platelet activating factor.

Transplantation. 1986; 42:86-88.

149- Camussi G, Niessen W, Tetta C, Saunders RN, Milgrom I. Release of platelet activating factor from rabbit heart perfused in vitro by sera with

transplantation alloantibodies.

Transplantation. 1987; 44: 113-118.

150- Pirotzky E, colliez P, Guilmard C, Schaefferbeke J, Braquet P. Cyclosporine-induced nephrotoxicity: preventive effect of a PAF-acether antagonist BN52021.

Transplantation Proceedings 1988; 3(38):665-669.

151- Makowka L, Miller Ch, Chachap P, Podesta L, Pan Ch, Pressley D, Mazzaferro V, Esquivel CO, Todo S, Banner B, Jaffe R, Saunders R, Starzl TE. Prolongation of pig-to-dog renal xenograft survival by modification of the inflammatory mediator response.

Ann. Surg. 1987; 206: 482-494.

152- Braquet P, Spinnewyn B, Demerle C, Hosford D, Marcheselli V, Rossowska M, Bazan NG. The role of platelet-activating factor in cerebral ischemia and related disorders.

Ann. N.Y. Acad. Sci. 1989; 559:296-312.

153- Frerichs KU, Feuerstein GZ. Platelet-activating factor. Key mediator in neuroinjury?

Cerebrovasc. Brain Metab. Rev. 1990; 2: 148-160.

154- Feuerstein G, Yue TL, Lysko PG. Platelet activating factor. A putative mediator in central nervous

system injury?

Stroke 1990; 21:III 90-94.

155- Wissner A, Schaub RE, Sum PE, Kohler CA, Goldstein BM. Analogues of platelet activating factor 4. Some modifications of the phosphocholine moiety.

J. Med. Chem. 1986; 29:328-333.

156- Kohayakawa M, Issoue K. Augmentation of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF)-induced human platelet activating factor by C-reactive protein.

Trombosis Research. 1986; 41:649-657.

157- Vigo C. Effect of C- reactive protein on platelet activating factor-induced platelet aggregation and membrane stabilization.

J. Biol. Chem. 1985; 260:3418-3422.

158- Mold C, Nakayama S, Holter TJ, Gewurz H, Duclos TW.

C-reactive protein is protective against *Streptococcus pneumoniae* infection in mice.

J. Exp. Med. 1981; 154:1703-1708.

159- Ponpipom M, Hwang S, Doebber T, Alton J, Alberts A, Biftu T, Brooker D, Bugianesi R, Chabala J, Gamble N, Graham D, Lam M, Wu M. Trans-2-[3-methoxy-5-methylsulfonyl-

4-preoxyphenyl]-5-[3,4,5-trimethoxy-phenyl]tetrahydrofuran (L-659,989), a novel, potent PAF receptor antagonist. **Biochem. Biophys. Res. Comm. 1988; 150:1213-1220.**

160- Hwang SB, Lam M, Alberts A, Bugianesi R, Chabala J, Ponpipom M. Biochemical and pharmacological characterization of L-659,989. **J. Pharm. Exp. Ther. 1988; 246:534-541.**

161- Dacey RG, Sande MA. Effects of probenecid on cerebrospinal fluid concentration of penicillin and cephalosporin derivatives. **Antimicrob. Agents. Chemother. 1974; 6: 437-444.**

162- Onofrio JM, Toews GB, Lipscomb MF, Pierce AK. Granulocyte-alveolar macrophage interaction in the pulmonary clearance of *Staphylococcus aureus*. **Am Rev. Resp. Dis. 1983; 127:335-341.**

163- Tuomanen E, Hill AR. Quantitation of bronchoalveolar lavage with methylene blue. **Am. Rev. Resp. Dis. 1984; 129: 146-147.**

164- Baughman RP, Bosken CH, Loudon RG, Hurtubise P, Wessler T. Quantitation of bronchoalveolar lavage with methylene blue. **Am. Rev. Respir. Dis. 1983; 128:266-270.**

165- Hwang SB, Lee CS, Cheah MJ, Shew TY. Specific receptor sites for 1-alkyl-glycero-3-phosphocholine (platelet activating factor) on rabbit platelet and guinea pig smooth muscle membranes.
Biochem. 1983; 22:4756-4763.

166- Bacterial meningitis and meningococemia. United States, 1978.
Morbidity and Mortality Weekly Report. 1979; 28:277.

167- Schlech III WF, Ward JI, Band JD, Hightower A, Fraser DW, Broome CV. Bacterial meningitis in the United States. 1978-1981.
JAMA 1985; 253:1749-1754.

168- Bryan JP, Rodrigues de Silva H, Tavares A, Rocha H, Scheld WM. Etiology and mortality of bacterial meningitis in Northeastern Brazil.
Rev. Infect. Dis. 1990; 12:128-135.

169- Wenger JD, Hightower AW, Facklam RR, Gaventa S, Broome CV. Bacterial meningitis in the United States 1986: Report of a multistate surveillance study.
J. Infect. Dis. 1990; 162:1316-1323.

170- Feigin RD, Dodge PR. Bacterial meningitis. Newer concepts of pathophysiology and neurologic sequelae.

Pediatr. Clin. North Am. 1976; 23:541.

171- Dodge PR, Schwartz MN. Bacterial Meningitis: A review of selected aspects II. Special neurological problems, post-meningitic complications and clinico-pathological correlations.

N. Engl. J. Med. 1965; 272:954.

172- Olsson R, Kirby JC, Romansky MJ. Pneumococcal meningitis in the adult. Clinical, therapeutic and prognostic aspects in forty-three patients.

Ann. Intern. Med. 1961; 55:545-549.

173- Carpenter RR, Peterdorsf RG. The clinical spectrum of bacterial meningitis.

Am. J. Med. 1962; 33:262-275.

174- Weiss W, Figueroa W, Shapiro WH, Flippin HF. Prognostic factor in pneumococcal meningitis.

Arch. Intern. Med. 1967; 120:517-524.

175- Täuber MG, Sande MA. Principles in the treatment of bacterial meningitis.

Am. J. Med. 1984; May 15: 224-230.

176- McAllister CK, O'Donohue JM, Beaty HN.

Experimental pneumococcal meningitis II. Characterization and quantitation of the inflammatory process.

J. Infect. Dis. 1975; 132:355-360.

177- Tuomanen E. Molecular mechanisms of inflammation in experimental pneumococcal meningitis.

Pediatr. J. Infect. Dis. 1987; 6: 1146-1149.

178- Saukkonen K, Sande S, Cioffe C, Wolpe S, Sherry B, Cerami A, Tuomanen E. The role of cytokines in the generation of inflammation and tissue damage in experimental Gram-positive meningitis.

J. Exp. Med. 1990; 71:439-448.

179- Saez-Llorens X, Ramilo O, Mustafa MM, Mertsola J, McCracken GH Jr. Molecular pathophysiology of bacterial meningitis: current concepts and therapeutic implications.

J. Pediatr. 1990; 116:671-684.

180- Hanahan DJ. Platelet activating factor: A biologically active phosphoglyceride.

Ann. Rev. Biochem. 1986; 55: 483-509.

181- Issekutz AC, Szpejda M. Evidence that platelet activating factor may mediate some acute inflammatory responses.

Laboratory Investigation. 1986; 54:275-281.

182- Hamasaki Y, Mojarad M, Saga T, Tai HH, Said SI. Platelet activating factor raises airway and vascular pressures and induces edema in lungs perfused with platelet-free solution.

Am. Rev. Resp. Dis. 1984. 129: 742-746.

183- Humphrey DM, McManus LM, Satouchi K, Hanahan DJ, Pinckard N. Vasoactives properties of acetyl glyceryl ether phosphorylcholine and analogues.

Laboratory Investigation. 1982; 46: 422-427.

184- Arditi M, Manogue KR, Caplan M, Yogev R. Cerebrospinal fluid cachectin/tumor necrosis factor and platelet activating factor concentrations and severity of bacterial meningitis in children.

J. Infect. Dis. 1990; 162:139-147.

185- Doerschuk CM, Winn RK, Coxson HO, Harlan JM. CD-18 Dependent and independent mechanisms of neutrophil emigration in the pulmonary and systemic microcirculation of rabbits.

J. Immunol. 1990; 144: 2327-2333.

186- Ballinger S, Dunlop N, Solvasen N, Gray B, Nahm, M, Svanborg C, Koopman W, Briles DE. Elevated serum IgM anti PC as a marker for elevated IgM rheumatoid factor and low CD5+ B cells in the elderly. Proceedings of the 91st

Meeting of the American Society of Microbiology, Dallas,
May 5 1991. American Society of Microbiology, Washington
DC, p 408.



